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Abstract
Background: Redox cycling compounds have been reported to cause false positive inhibition of proteases in drug discovery
studies. This kind of false positives can lead to unusually high hit rates in high-throughput screening campaigns and require
further analysis to distinguish true from false positive hits. Such follow-up studies are both time and resource consuming.
Methods and Findings: In this study we show that 5-aminoquinoline-8-ol is a time-dependent inactivator of cathepsin B
with a kinact/KI of 36.7613.6 M
21s
21 using enzyme kinetics. 5-Aminoquinoline-8-ol inhibited cathepsins H, L and B in the
same concentration range, implying a non-specific mechanism of inhibition. Further analogues, 4-aminonaphthalene-1-ol
and 4-aminophenol, also displayed time-dependent inhibition of cathepsin B with kinact/KI values of 406.4610.8 and
36.561.3 M
21s
21. No inactivation occurred in the absence of either the amino or the hydroxyl group, suggesting that the 4-
aminophenol moiety is a prerequisite for enzyme inactivation. Induction of redox oxygen species (ROS) by 4-aminophenols
in various redox environments was determined by the fluorescent probe 29,79-dichlorodihydrofluorescein diacetate.
Addition of catalase to the assay buffer significantly abrogated the ROS signal, indicating that H2O2 is a component of the
ROS induced by 4-aminophenols. Furthermore, using mass spectrometry, active site probe DCG-04 and isoelectric focusing
we show that redox inactivation of cysteine cathepsins by 5-aminoquinoline-8-ol is active site directed and leads to the
formation of sulfinic acid.
Conclusions: In this study we report that compounds containing the 4-aminophenol moiety inactivate cysteine cathepsins
through a redox-based mechanism and are thus likely to cause false positive hits in the screening assays for cysteine
proteases.
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Introduction
Cathepsins are lysosomal cysteine proteases belonging to the
papain-subfamily C1A of the clan CA of cysteine proteases [1]. The
group comprises 11cathepsins(cathepsinsB,C, F,H,K,L, O,S,V,
W and X) which act predominantly as endopeptidases and are for
the most part located intracellularly in endolysosomal vesicles [2].
For this reason it was long believed that their primary function was
protein turnover within lysosomes [3]. However, it was later
discovered that individual cathepsins could also be associated with
more specific functions. For example, cathepsin K is abundant in
osteoclasts, where it plays a vital role in the resorption and
remodeling of bone [4], and cathepsin S has been implicated in
major histocompatibility class II antigen presentation [5]. However,
for several cathepsins, dysregulation at the protein, activity and
localization levelscanlead to numerous pathologies. One of the best
studied examples is the causative role of cathepsin B in malignant
diseases where it was shown to be involved in tumor formation,
growth and invasion, as well as to participate in angiogenesis [2].
Much is now known about the cysteine cathepsins. Their crystal
structures, physiological and pathological involvement as well as
their regulatory mechanisms constitute them as attractive targets
for drug discovery [6,7]. Cathepsins K, S and B have been
validated as effective drug targets in osteoporosis, immune diseases
and cancer, respectively [2,6,7]. Several drug discovery strategies
have been employed in the search for cathepsin inhibitors, such as
isolation, characterization [8,9] and evaluation of compounds of
natural origin [10], virtual screening of large libraries of small
molecules [11], fragment-based screening [12] and high-through-
put screening of large compound libraries [13], to name a few.
However, such approaches can often result in nonspecific false
positives, characterized by steep dose-response curves, lack of clear
structure-activity relationships and high sensitivity to assay
conditions [14]. Several mechanisms have been proposed for
these artifacts, including the involvement of chemically reactive
molecules, molecules that may interfere with the assay signal, and
molecules that form aggregates and cause partial denaturation of
the target, manifesting themselves as nonspecific or promiscuous
enzyme inhibitors [14,15].
In the last decade a new mechanism of false positive inhibition
has been reported for proteases that possess functional groups
susceptible to redox modification [16–20]. The molecules causing
PLoS ONE | www.plosone.org 1 November 2011 | Volume 6 | Issue 11 | e27197the artifact were termed redox cycling compounds (RCC) due to
the formation of mM concentrations of hydrogen peroxide in the
presence of reducing agents used in the assay buffers for high-
throughput screening (HTS) [16,17]. H2O2 generated by such
molecules induces oxidation of accessible cysteine, tryptophan,
methionine, histidine, or selenocysteine residues, in this way
causing false positive inhibition of several classes of proteases, such
as protein tyrosine phosphatases [17,19], cysteine proteases
(cathepsins and caspases) [18,20,21] and metalloenzymes
[16,21]. This kind of false positive can lead to unusually high hit
rates [18] in HTS campaigns, which require further analysis to
distinguish true from false positive hits. Such follow-up studies are
both time and resource consuming and, if nonspecific inhibitors
are not recognized as such, they may be even deposited in
screening databases and flagged active [16,22].
We identified 5-nitroquinolin-8-ol as a selective and potent
inhibitor of cathepsin B using virtual-screening, enzyme kinetics
and cell-based assays in a previous study [23]. By verifying the
structural requirements for cathepsin B inhibition we have now
discovered that the 5-amino analogue, 5-aminoquinolin-8-ol (1),
displays time-dependent inhibition. The inhibition has been shown
to be concentration dependent, nonspecific, irreversible and active
site directed, using enzyme kinetics, mass spectrometry, the DCG-
04 probe and isoelectric focusing (IEF). Furthermore, the
inhibition is shown to depend on reactive oxygen species (ROS)
using the fluorescent probe 29,79-dichlorodihydrofluorescein
diacetate (H2DCFDA) and is abolished by catalase. Here we
report that compounds containing the 4-aminophenol moiety
inactivate cysteine cathepsins through a redox-based mechanism
and are thus likely to cause false positive hits in screening assays for
inhibition of cysteine proteases.
Materials and Methods
Reagents
5-Aminoquinolin-8-ol (1) (95%), 5-nitroquinolin-8-ol (2) (96%),
4-aminophenol (6)( $99%), phenol (7)( , 99%), and aniline (8)
($99.5%) were purchased from Sigma-Aldrich and used without
further purification. 4-Aminonaphthalen-1-ol hydrochloride (3)
(90%), quinolin-8-ol (4) (for analysis ACS) and quinolin-5-amine
(5) (for analysis ACS) were purchased from Acros Organics and
used without further purification (Figure 1). Cystine, cysteine and
DTT were obtained from Sigma-Aldrich, and H2O2 from Merck.
Irreversible cathepsin B specific inhibitor CA-074 was obtained
from Bachem and the active site probe DCG-04 was kindly
provided by Dr. Matthew Bogyo.
Enzymes and assay buffers
Human recombinant cathepsin B was prepared as reported
[24]. Human cathepsin H was isolated from human liver [25] and
human recombinant cathepsin L was expressed in E. coli [26].
Cathepsins B, L and H were assayed in 100 mM phosphate buffer,
pH 6.0, 100 mM acetate buffer, pH 5.5 and 100 mM phosphate
buffer, pH 6.8, respectively. Each contained 0.1% PEG 8000
(Sigma-Aldrich) and 1.5 mM EDTA (Serva). Activation buffers
were prepared by adding reducing agent to the assay buffer to a
final concentration of 5 mM. Prior to the assay each enzyme was
activated in the activation buffer for 5 min at 37uC.
Time-dependent inhibition of cathepsins by 4-
aminophenols
To evaluate the inhibitory activity of the tested compounds the
following substrates were used: Z-Arg-Arg-AMC (Bachem) at
60 mM, Z-Phe-Arg-AMC (Bachem) at 2 mM and Arg-AMC
(Biomol) at 10 mM for cathepsins B, L and H, respectively. 5 ml
of inhibitor or dimethyl sulfoxide (DMSO) and 5 ml of the
appropriate substrate were added to the wells of a black 96-well
microplate. The reaction was initiated by adding 90 mlo f
cathepsins B, L or H at final concentrations of 400 pM, 200 pM
or 2.5 nM, respectively. Formation of fluorescent degradation
product was monitored continuously at 380 nm620 nm excita-
tion and 460 nm610 nm emission on a Tecan Safire2 reader
(Tecan) using minimal kinetic interval at 37uC. All kinetic
measurements were performed in duplicate. Progress curves
obtained with a range of concentrations of inhibitor were fitted
to the equation [27] P=v st + (vi 2 vs)(1 2 e
2kobst)/kobs, where P
denotes the product concentration in relative fluorescence units
(RFU) at time t; vi and vs are the initial and steady-state velocities
and kobs is the apparent first-order rate constant for the
establishment of the final steady-state equilibrium. Plots of kobs
values versus inhibitor concentration yielded a linear fit describing
a single-step mechanism for the irreversible inactivation of the
enzyme, with a slope corresponding to the second-order rate
constant kinact/KI.
Fluorescent probe H2DCFDA for ROS detection
H2DCFDA (D6883, Sigma) was used as described elsewhere
with minor modifications [28]. To hydrolyze the ester function-
ality of the probe for use in a cell-free assay, H2DCFDA was
dissolved in DMSO at 1 mM, diluted to 100 mM with 0.01 N
NaOH and kept in the dark at room temperature (RT) for 30 min.
The reaction was performed in a black 96-well microplate, adding
to each well 10 mL of the de-esterified probe solution, 5 mlo f
DMSO or inhibitor at a final concentration of 500 mM and 85 ml
of the activation buffer with different redox agents (redox-free,
cystine, cysteine or DTT, each at 5 mM). In a parallel experiment
catalase from bovine liver (C9322, Sigma) was added to the
activation buffer to a final concentration of 200 U/ml. The
reaction was continuously monitored for 15 min using 535 nm
excitation and 485 nm emission filters on a Tecan GENios reader
Figure 1. 4-Aminophenol derivatives and their analogues used
in this study.
doi:10.1371/journal.pone.0027197.g001
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were performed in duplicate.
Active site probe DCG-04
1 mg cathepsin B in the activation buffer with a suitable redox
agent at 5 mM was incubated with 200 mM respective inhibitor
for 1 h at RT. Samples were labeled with 2 mM DCG-04 for 1 h
at RT, separated by 12.5% SDS-PAGE and transferred to a
nitrocellulose membrane. The latter was blocked overnight with
0.5% Tween 20 in PBS at 4uC and incubated with 1 mg/ml
streptavidin-horseradish peroxidase (Sigma-Aldrich) for 1 h at RT.
The membrane was washed five times and the spots on the
membrane were visualized with 0.5 mg/ml 3,39-diaminobenzidine
(Sigma-Aldrich) and 0.0005% (v/v) H2O2.
Isoelectric focusing
2 mg cathepsin B in the activation buffer with no reducing
agent, cystine, cysteine or DTT at 5 mM, respectively was
incubated with DMSO or CA-074 at 50 mM for 15 min at RT
to prevent redox changes to the active site thiol group. Samples
were then incubated with DMSO, compound 1 or H2O2 at
500 mM or 490 mM, respectively for 5 h at RT. 4 ml of each
sample was loaded on the precast isoelectric focusing gel PhastGel
IEF (pI range 3.0–9.0) (GE Healthcare) and separated on the
Phast System (GE Healthcare) according to the protocol of the
manufacturer. After separation, gels were developed on the Phast
System using Coomassie blue staining. pIs of individual bands
were determined from a calibration curve (Figure S5) obtained
using the Broad range pI calibration kit (pH 3.0–10.0) (GE
Healthcare).
Mass spectrometry
Cathepsin B (4.4 mM) was incubated with DMSO or CA-074
(44 mM) in the activation buffer containing 1 mM cysteine for 1 h
at RT. Compound 1 (500 mM) or DMSO were added and
incubated with cathepsin B for additional 5 h at RT. The mixtures
were then dialyzed against water using Microcon Centrifugal
Filter Devices YM-10 (Millipore). Samples were prepared by
adding an equal volume of acetonitrile containing 0.1% formic
acid and analyzed by ESI-MS on an AutoSpec Q instrument
(Micromass).
Results
Time-dependent irreversible inactivation of cathepsin B
by compound 1
Under redox-free conditions, compound 1 (Figure 1) potently
inhibited cathepsin B in a dose- and time-dependent manner
(Figure S1). The activity of cathepsin B decreased in a pseudo-first
order process and plotting the apparent first-order rate constant
(kobs) versus inhibitor concentration yielded a linear fit describing a
single-step mechanism for irreversible inactivation of the enzyme
with a second-order rate constant, kinact/KI, of 36.7613.6 M
21s
21
(Table 1). This inactivation rate was decreased approximately 10-
fold when reducing agent 5 mM cysteine or 5 mM DTT was
Figure 2. Time-dependence of the inhibition of cathepsin B by compound 1 in the presence of 5 mM DTT. The increasing
concentrations of compound 1 were premixed with the fluorogenic substrate Z-Arg-Arg-AMC (60 mM) and the time course of the reaction was
measured after the addition of cathepsin B (400 pM) using excitation and emission wavelengths of 380 and 460 nm, respectively. The solid lines
represent the raw data which were fitted to the equation P=v st + (vi 2 vs)(1 2 e
2kobst)/kobs, from which the apparent first-order rate constant kobs
was obtained. Insert: Plot of the kobs values versus concentration of compound 1. The line represents a linear fit describing a single-step mechanism
for the irreversible inactivation of the enzyme, with a slope corresponding to the second-order rate constant kinact/KI.
doi:10.1371/journal.pone.0027197.g002
Table 1. Second-order rate constants for inactivation of
cathepsins B, H and L by compound 1 in the presence of
different redox compounds.
kinact/KI (M
21s
21)
a
Cathepsin B Cathepsin H Cathepsin L
Redox-free 36.7613.6 35.3460.75 107.9610.5
Cystine 41.3616.4 28.063.9 41.963.6
Cysteine 2.460.1 37.961.0 4.363.2
DTT 3.561.7 7.760.45 5.361.4
ameans 6 SD, n$2. Experimental details are described in the Materials and
methods section.
doi:10.1371/journal.pone.0027197.t001
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21s
21 and
3.561.7 M
21s
21, respectively) (Table 1). A representative prog-
ress curve depicting the time dependence of the inhibition of
cathepsin B by compound 1 and plot of kobs versus compound
concentration are shown in Figure 2. Cystine did not influence the
inactivation rate significantly.
The inactivation of cathepsin B by compound 1 is
nonspecific with regard to other cathepsins
To evaluate whether compound 1 was a cathepsin B specific
inhibitor we tested the compound against two related cathepsins,
the aminopeptidase cathepsin H and the endopeptidase cathepsin
L. Results show that compound 1 inhibited cathepsin H in a
manner similar to cathepsin B under non-reducing conditions
(redox-free and 5 mM cystine) since the inactivation rates
remained almost the same (Table 1). Furthermore, the inactivation
rate was also lowered in the presence of the reducing agent DTT,
as is the case with cathepsin B. However, when cysteine was added
to the activation buffer the inactivation rate was the same as under
non-reducing conditions and did not decrease. When inhibitory
activity of compound 1 was evaluated on cathepsin L the trend of
inactivation was similar to the cathepsin B inactivation – a 10–fold
decrease in inhibition after introduction of reducing agents
(Table 1). Although the inactivation rate in the redox-free
conditions was three times higher than that for cathepsin B, the
differences in the inactivation rates between individual cathepsins
are too small to conclude that compound 1 is a specific cathepsin B
inhibitor.
Structural requirements for cathepsin inactivation
The structural requirements for the time-dependent irreversible
inactivation of cathepsin B by compound 1 were determined by
testing its structural analogues (compounds 2–8) (Figure 1) against
cathepsin B in two representative redox environments, redox-free
and 5 mM cysteine. Results show that the 4-aminophenol moiety
is a prerequisite for cathepsin B inactivation. In the redox-free
conditions only compounds 1, 3 and 6 (Figure S1) displayed time-
dependent irreversible inhibition. Compound 2 showed reversible
inhibition whereas compounds 4, 5, 7 and 8 displayed no
inhibition at all. Inactivation rates were determined for com-
pounds 1, 3 and 6 (Table 2). Compound 3 is an 11-fold more
potent inhibitor of cathepsin B than compound 1, whereas
compound 6 inhibits cathepsin B with the same potency as
compound 1 under the redox-free conditions. Interestingly, when
compounds were tested in a reducing environment (5 mM
cysteine), only compounds 1 and 3 retained time-dependent
irreversible inactivation of cathepsin B (Figure S2). Inactivation
rates were determined (Table 2) and compound 3 proved a 42-fold
more potent inhibitor of cathepsin B than compound 1 in the
presence of 5 mM cysteine. On the other hand, compound 6 did
not display the time-dependent irreversible behavior within the
time course of the assay in the presence of 5 mM cysteine as it did
under the redox-free conditions. Compound 2 retained its
reversible inhibition of cathepsin B whereas compounds 4, 5, 7
and 8 did not display inhibition of cathepsin B as in the redox-free
conditions.
Time-dependent irreversible inactivation of cathepsin B
by H2O2
Since there is no electrophilic warhead in the structure of
compound 1 that could explain the irreversible behavior of
cathepsin B inhibition, and since RCCs have been reported to be
able to generate H2O2 in HTS buffers [16], we studied the nature
of cathepsin B inhibition by H2O2. In the redox-free environment
H2O2 inhibited cathepsin B as a time-dependent irreversible
inhibitor (Figure S1) with inactivation rate of 43.9611.1 M
21s
21
(Table 2). However, in the presence of 5 mM cysteine no such
irreversible inhibition was observed during the time course of the
experiment (Figure S2).
Cathepsin inactivation by 4-aminophenols is ROS
dependent
To establish whether ROS induced by 4-aminophenols are
mediators of time-dependent irreversible inactivation of cathep-
sins, a probe, H2DCFDA, was used. The latter upon de-
esterification and oxidation becomes fluorescent and is used for
ROS detection. In the presence of compound 1 an approximately
6–fold greater production of ROS was observed in comparison
with DMSO control when redox-free, 5 mM cystine and 5 mM
cysteine conditions were used (Figure 3A). A significantly higher
response (9.0–fold increase) was obtained with 5 mM DTT as
reducing agent in the activation buffer. The implication that H2O2
is one of the ROS induced by compound 1 was corroborated by
the addition of catalase, which degrades H2O2 to O2 and H2O.
Catalase significantly abrogated the ROS signal under all redox
conditions used, confirming H2O2 as one of the ROS induced by
compound 1. When compound 3 was evaluated for ROS
production a similar, albeit less pronounced, trend was observed
(Figure 3B). The ROS signal was again higher with 5 mM DTT
used as a reducing agent (3.5–fold increase) whereas the increase
of the ROS signal under redox-free, cystine and cysteine
conditions was smaller (,1.5–fold increase). Upon addition of
catalase, a significant reduction in H2DCFDA signal was evident,
as was the case with compound 1. For compound 6 the increase in
ROS signal was only minor 21.7, 1.6 and 1.5–fold increases for
redox-free, 5 mM cystine and 5 mM DTT conditions (Figure 3C).
Furthermore, compound 6 did not induce ROS production in the
presence of 5 mM cysteine. However, addition of catalase to the
assay buffer significantly decreased the ROS signal under redox-
free, 5 mM cystine and 5 mM DTT conditions. These results
indicate that compounds 1 and 3 are capable of inducing ROS
production in various redox systems with the most pronounced
production in the presence of DTT. Compound 6 is also capable
of induction of ROS, although to a lesser extent.
Cathepsin B inactivation by 4-aminophenols is active site
directed
To determine whether the inactivation of cathepsin B by 4-
aminophenols is due to the oxidation of the active site thiol rather
than other cysteine residues we performed three independent
experiments. The first was based on the use of the active site probe
Table 2. Second-order rate constants for inactivation of
cathepsin B by compounds 3 and 6 and by H2O2 under
different redox states.
kinact/KI (M
21s
21)
a
36 H 2O2
Redox-free 406.4610.8 36.561.3 43.9611.1
Cysteine 101.163.3 NR NR
ameans 6 SD, n$2. NR No reaction observed. Experimental details are
described in the Materials and methods section.
doi:10.1371/journal.pone.0027197.t002
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cathepsins and can be detected through a biotin tag, the intensity of
labeling correlating with protease activity. In the first instance,
compound 1 was tested in the presence of various redox systems. In
non-reducing environments (redox-free and 5 mM cystine) com-
pound 1inhibitedcathepsinB activityby60%(Figure 4Aand C).In
the presence of 5 mM cysteine and 5 mM DTT the inhibition was
reduced to 15% and 25%. Cathepsin B activity was completely
inhibited by the specific irreversible inhibitor CA-074, which was
used as a positive control. Binding of CA-074 into the active site of
the enzyme was not affected by the redox environment as shown in
Figure S3. Compounds 2–8 and H2O2 were also tested for their
ability to prevent DCG-04 from binding into the active site cleft. In
the redox-free system only compounds 3, 6 and H2O2 inhibited
cathepsin B activity – by 66, 70 and 60%, respectively (Figure 4B
and D). No significant change in cathepsin B activity was seen with
compounds 2, 4, 5, 7 and 8. However, when 5 mM cysteine was
used as a reducing agent, compounds 2–8 did not significantly alter
DCG-04 binding and, of 3, 6 and H2O2, only compound 3
displayed inhibition, at 32% (Figure S4).
In a second experiment, redox transformations of the active site
thiol group to either sulfenic, sulfinic or sulfonic acid were
demonstrated through changes in pI of the enzyme using IEF.
Recombinant cathepsin B, expressed in E. coli, was found to
consist of 2 isoforms with pI values of 5.46 and 5.35 (Figure 5).
These pI values are close to the predicted pI value for the single
chain form of the enzyme (5.24) [30] and are in line with pI values
for human liver cathepsin B (4.6–5.2) [31] and for cathepsin B
isolated from human osteosarcoma cell line (5.5–5.9) [32]. The
isoform with the pI value of 5.46 corresponds to the active form,
whereas the band at the pI value of 5.35 can be attributed to the
oxidized enzyme form, since addition of H2O2 as a positive control
induced a shift from the active to the oxidized isoform. Compound
1 also induced the oxidized form of cathepsin B. The ratio
between the active and the oxidized form of cathepsin B was
determined with scanning and quantification of band intensities.
DMSO-treated cathepsin B displayed 1:0.60 and 1:0.61 ratio
between the active and the oxidized form of cathepsin B in the
presence of 5 mM cysteine and DTT, respectively. Treatment
with compound 1 changed the ratio in favor of the oxidized form
to 1:0.79 and 1:0.91, respectively. Additionally, samples were
pretreated with CA-074 which binds irreversibly into the active
site cleft, thus preventing oxidation of the active site thiol by
compound 1 or by H2O2. Hence, the pretreatment caused the
oxidized isoform to disappear and only one band was visible, in
this way confirming the oxidation of the active site thiol of
cathepsin B by compound 1.
Additionally, mass spectrometry was used to identify the
compound 1-induced protein modification of cathepsin B. Mass
spectrometry analysis of DMSO-treated cathepsin B resulted in
one major peak with mass of 2817461 Da (Figure 6). After 5 h
incubation with compound 1 (500 mM) the peak shifted to a mass
of 2820461 Da, consistent with the addition of two oxygen atoms
and formation of sulfinic acid. To show that this modification is
active-site directed cathepsin B was treated with CA-074 (44 mM)
prior to addition of compound 1. This resulted in an increase in
mass of 2855861 Da, corresponding to the formation of the
covalent adduct between cathepsin B and CA-074 (calculated mass
of bound fragment: 384.21 Da). CA-074 is known to covalently
react only with the active site thiol group [10] leaving other thiol
groups free for modification. However, no peaks were evident that
could be attributed to CA-074-cathepsin B covalent adducts with
two additional oxygen atoms. Thus, compound 1 induces
formation of sulfinic acid from the active site thiol group under
the experimental conditions used.
Discussion
These results demonstrate that 4-aminophenols inactivate
cysteine cathepsins B, H and L in a dose- and time-dependent
manner. The inhibition is mediated by ROS, of which H2O2 is
shown to be a major constituent. The inactivation of cysteine
cathepsins arises from specific oxidation of the thiol group of the
catalytic Cys29 to sulfinic acid.
Cysteine cathepsins are small monomeric enzymes with
molecular weight of approximately 30 kDa and possess a
Figure 3. 4-Aminophenols induce formation of ROS in various
redox systems as shown by the fluorescent probe H2DCFDA.
10 mL of the de-esterified probe (see Methods) and 5 ml of DMSO
(control) or compound 1 (A), 3 (B) and 6 (C) (500 mM) were added to
the wells of a black microplate and after addition of 85 ml of activation
buffer with a corresponding redox agent the reaction was monitored at
535 nm excitation and 485 nm emission wavelengths for 15 min at 37 ˚C.
In a parallel experiment catalase (200 U/ml) was added to the activation
buffer. All measurements were performed in duplicate and the data are
representative of three independent experiments.
doi:10.1371/journal.pone.0027197.g003
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domains form a V-shaped active site cleft in the middle of which the
catalytic triad is located [33]. The catalytic Cys25 (papain
numbering) possesses an unusually low pKa (, 2.5–3.5) [34] for a
cysteine residue and is in the form of a thiolate which forms a
thiolate-imidazolium ion pair with His159, located on the opposite
site of the active site cleft. The low pKa of the thiolate enhances its
catalytic function as a nucleophile, however, it also increases its
susceptibility to inactivation by ROS, such as H2O2 [35]. To avoid
false positive inhibition by RCCs during the search for new
cathepsin inhibitors a simple assay that could distinguish nuisance
redox compounds from well-behaved inhibitors would be useful.
Two high throughput plate-based assays have recently been
reported. The first detects small molecule redox activity through
oxidative transformation of resazurin to resorufin [21] while, in the
second, H2O2 generated by RCCs is detected with horseradish
peroxidase mediated oxidation of phenol red [36]. Using the latter,
Soares et al. screened the National Institutes of Health Small
MoleculeRepositorylibraryforRCCs,andeightdifferentstructural
classes of RCCs – ortho-quinones, para-quinones, pyrimidotriazine-
diones, arylsulfonamides, nitrothiophene-2-carboxylates, tolyl hy-
drazides, acetamido-dihydroisoxazolopyridine-diyl diacetates and
pyrrolo-quinoxalinchlorobenzenamides were revealed [22]. Of the
reported structural classes the quinone group appears to be the best
characterized as they are reported to be redox-based inactivators of
caspase-3[20],caspase-8[18],proteintyrosine phosphatase1B [19]
and protein tyrosine phosphatase a [17]. Here, we report a novel
small-molecule scaffoldcapable ofinducing oxidative inactivation of
cysteine cathepsins through ROS generation.
As part of a previous study we discovered that compound 1
inhibits cathepsin B in a time-dependent manner. Given that it
lacks an electrophilic motif, typically required for irreversible
Figure 4. Compound 1 and its analogues (compounds 2–8) inactivate cathepsin B through an active site directed mechanism.
Cathepsin B (1 mg) was incubated with compound 1 (200 mM) in activation buffers containing various redox agents at 5 mM (A, C) or with
compounds 2–8 and H2O2 (200 mM) in the activation buffer in the absence of redox compounds (B, D) and subsequently labeled with DCG-04 (2 mM).
Samples were then analyzed by SDS-PAGE and Western blotting. The band intensities indicate cathepsin B activity. The graphs of residual cathepsin B
activity were obtained by dividing individual band intensities with that of the suitable control (C, D). Data shown here are presented as means 6 SD,
n=2.
doi:10.1371/journal.pone.0027197.g004
Figure 5. Compound 1 induces oxidative changes in the active site of cathepsin B. Cathepsin B (2 mg) was incubated with DMSO or CA-074
(50 mM) for 15 min at RT in activation buffer with respective reducing agent at 5 mM. Afterwards, the samples were incubated with DMSO,
compound 1 (500 mM) or H2O2 (490 mM) for 5 h at RT. 4 ml of each sample was then loaded on precast isoelectric focusing gel (pI range 3.0–9.0),
separated on the Phast System and stained with Coomassie blue. Black and white arrows are used to denote the active and the oxidized isoforms of
cathepsin B, respectively.
doi:10.1371/journal.pone.0027197.g005
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PLoS ONE | www.plosone.org 7 November 2011 | Volume 6 | Issue 11 | e27197inactivation of the enzyme, and that time-dependent behavior is
one of the first indicators of RCCs [16], redox-based inactivation
of cathepsin B through ROS generation was suspected. Com-
pound 1 is seen to be a potent irreversible inhibitor of cathepsin B
in redox-free and cystine systems (Table 1). The second-order rate
constants are comparable with those reported for nonspecific
redox inactivation of protein tyrosine phosphatase a by ortho-
quinones (67.8 M
21s
21) [17]. Under reducing conditions the
inactivation by compound 1 was significantly attenuated. These
results contrast with reports that redox inactivation by RCCs
requires the presence of strong reducing agents like DTT or tris(2-
carboxyethyl)phosphine (TCEP) and is not observed in the
presence of milder reducing agents, such as glutathione, b-
mercaptoethanol, cysteine, or in their absence [17–20]. However,
in the latter studies, quinone-like compounds were used, which
require a strong reducing agent like DTT to reduce the quinone
moiety to hydroquinone which could then undergo synproportio-
nation with a quinone molecule and enter the redox cycle [16].
Our results thus establish that 4-aminophenols are capable of
entering the redox cycle without intervention of a reducing agent.
Since RCCs are known for their promiscuous bioactivity
profiles and can inhibit different classes of enzymes, such as
protein tyrosine phosphatases and cysteine proteases (cathepsins
and caspases) [16], we sought to discover whether compound 1 is
able to distinguish between individual cathepsins. Cathepsins B, H
and L were chosen based on their substrate specificities. Cathepsin
H acts as an aminopeptidase, cathepsin L as an endopeptidase and
cathepsin B can cleave its substrates both as an endopeptidase and
a dipeptidyl carboxypeptidase [37]. Compound 1 inhibited all
three enzymes within the same concentration range (Table 1) in
non-reducing and reducing conditions, with no indication of inter-
cathepsin specificity.
A series of compound 1 analogues (compounds 2–8) were also
tested for the inhibition of cathepsin B (Figure S1 and S2) to
elucidate which structural features are responsible for the time-
dependent inactivation. Of the entire analogue series only
compounds 1, 3 and 6 displayed time-dependent inactivation in
the non-reducing environment (Table 2) leading to the conclusion
that the time-dependent irreversible inactivation of cathepsin B
requires the complete 4-aminophenol moiety. As is evident from
compound 3 the quinoline nitrogen is not a prerequisite for
enzyme inactivation. On the contrary, compound 3 inhibited
cathepsin B 12-fold and 42-fold better than compound 1 under
non-reducing and reducing conditions. Furthermore, the aromatic
ring in compounds 1 and 3 is not essential for cathepsin B
inactivation under redox-free conditions since compound 6,
lacking the quinoline or naphthalene core, retains its inhibitory
activity against cathepsin B. However, both amino and hydroxyl
group in the para position are essential for cathepsin B inactivation
since compound 7 lacking the amino group or compound 8
lacking the hydroxyl group lose their time-dependent inactivation.
Of the different aminophenols (2-, 3- and 4-aminophenol), only 4-
aminophenol was able to non-enzymatically induce hydroxyl
radical formation [38], therefore, we did not examine the 2- and 3-
substituted aminophenols for cathepsin B inhibition.
Of the three inhibitors (compounds 1, 3 and 6) that behaved in
a time-dependent manner in the non-reducing environment, only
compounds 1 and 3 retained their time-dependent inhibition in a
reducing environment (Figure S2). Although compound 6 was still
able to inhibit cathepsin B, it did not exhibit pseudo-first order
inactivation kinetics, but behaved as a reversible inhibitor.
Similarly, H2O2 also behaved as a time-dependent inhibitor
under non-reducing conditions (Table 2). The value, (kinact/KI of
43.9611.1 M
21s
21) is in line with those for the H2O2 induced
inactivation of the related cysteine protease papain (kinact/KI of
61.7 M
21s
21) [35] and protein tyrosine phosphatases (kinact/KI of
10–20 M
21s
21) [39]. However, in the presence of 5 mM cysteine,
it inhibits cathepsin B as a reversible inhibitor. These results
indicate H2O2 as one of the components of ROS induced by
compound 6.H 2O2 induces oxidation of the papain active site
thiol group to inactive sulfenic acid in the absence of reducing
agents, a step which is almost completely reversed by addition of
cysteine [35]. Additionally, protein tyrosine phosphatases react
with H2O2, yielding the sulfenic acid of the active site cysteine,
which can be reduced back to the active thiolate species with
glutathione, DTT, b-mercaptoethanol and cysteine [39].
4-aminophenols were shown to induce formation of ROS in
various redox environments in the presence of atmospheric oxygen
using the fluorescent probe H2DCFDA (Figure 3). The increase in
ROS production was most pronounced with compound 1,
followed by compound 3 and compound 6. Moreover, addition
of catalase to the activation buffer significantly abrogated
induction of ROS signal by compounds 1 and 3 suggesting
H2O2 as one of the components of induced ROS [16]. Although,
H2DCFDA is known to have low reactivity towards H2O2, the
latter can serve as a source of additional ROS, such as hydroxyl
radical, which is readily detected with H2DCFDA probe [40].
Cathepsin B possesses 14 cysteine residues, of which 12 are
involved in the formation of disulphide bonds, Cys29 is part of the
catalytic triad and Cys240 is unpaired [41]. The pKa of sulfhydryl
groups of most cysteine residues in proteins is approximately 8.5 and
they do not react at physiologically significant rates with H2O2 unless
t h er e a c t i o ni sc a t a l y z e d[ 1 6 ] .O nt h eo t h e rh a n d ,t h ea c t i v es i t e
cysteine of cathepsin B exists as a thiolate anion with a much lower
pKa rendering it more susceptible to oxidative inactivation.
Compound 1 prevented DCG-04 from binding into the active site
in reducing and non-reducing environments, confirming the active
site directed inactivation (Figure 4). In addition, compounds 3 and 6,
as well as H2O2, abolished DCG-04 binding in a redox-free
environment, suggesting a common active site directed mechanism
of cathepsin inactivation for all 4-aminophenols. The result was
confirmed by IEF, where addition of compound 1 resulted in
increased intensity of a band corresponding to an oxidized form of
cathepsin B. The latter completely disappeared after pretreatment
with CA-074 (Figure 5), a cathepsin B specific inhibitor binding
irreversiblytotheactivesitecysteine,therebypreventingitsoxidation.
Additionally, mass spectrometry analysis was used to identify the
modifications of cathepsin B by compound 1. Treatment of cathepsin
B with compound 1 induced formation of sulfinic acid and
pretreatment with CA-074 prevented redox-changes to the enzyme
confirming that inactivation of cathepsin B was active site-directed
(Figure 6). Active site-directed inactivation also appears to be
important for other reported classes of RCCs. A recent study
reported the oxidative transformation of caspase-3 catalytic cysteine
to sulfonic acid by isoquinoline-1,3,4-trione derivatives [20]. Two
independent groups have also shown the transformation of the active
site thiol group of cathepsin L and protein tyrosine phosphatase 1B to
sulfinic and to sulfonic acid by RCCs [19,21].
Figure 6. Identification of compound 1-induced cathepsin B modification by mass spectrometry. Cathepsin B (4.4 mM) was treated with
DMSO or CA-074 (44 mM) and after 1 h compound 1 (500 mM) or DMSO were added and incubated for additional 5 h at RT. The mixtures were then
dialyzed against water and analyzed by ESI-MS.
doi:10.1371/journal.pone.0027197.g006
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4-aminophenol induced inactivation of cathepsins (Figure 7). 4-
Aminophenol is light sensitive and undergoes non-enzymatic
oxidation in aqueous solutions in the presence of molecular oxygen
to form the 4-aminophenoxy radical [38,42–44]. The 4-amino-
phenoxy radical then either undergoes disproportionation to yield
the p-benzoquinoneimine or reacts with O2 to form the superoxide
anion and the quinoneimine species [42]. The superoxide anion
can then react with 4-aminophenol and generate H2O2 and the 4-
aminophenoxy radical [17], thus completing the redox cycle. This
proposed mechanism of redox cycling explains the lack of need for
strong reducing agents like DTT and TCEP, as seen with
quinone-like RCCs [16]. Moreover, it also explains why addition
of the reducing agents used in this study diminishes the
inactivation rates by 10–fold from those in non-reducing
environments. They appear to protect 4-aminophenol from
oxidation by air, as was reported for hydrazine and antioxidants
such as ascorbate, glutathione and NADPH [45,46]. The resulting
ROS readily react with the active site thiolate anion, forming in
the first step a sulfenic acid of cysteine (2SOH) which is fully
reducible back to cysteine in the presence of reducing agents,
unlike sulfinic acid (2SO2H), which is formed form upon further
oxidation of sulfenic acid in the second step [39].
However, irreversible inactivation of cathepsins by 4-amino-
phenols can also be explained by a mechanism involving the
formation of covalent adducts of p-benzoquinoneimines with the
active site thiol group. This mechanism was proposed to be the
main source of hepatotoxicity of acetaminophen. Its metabolic
activation leads to the formation of a toxic metabolite, N-acetyl-p-
benzoquinoneimine. The latter is preferentially conjugated with
glutathione, but once glutathione is depleted the toxic metabolite
binds to other nucleophilic groups in the cell, in this way
accounting for the toxicity [47]. Nonetheless, the attenuation of
ROS induction by catalase and of cathepsin inhibition in the
presence of various reducing agents as well as mass spectrometry
data support our hypothesis that 4-aminophenols inactivate
cysteine cathepsins through oxidative inactivation. A recent study
has also shown that 4-aminophenol induces H2O2 formation in
cell medium, impairing LLC-PK1 cell viability, in this way
exerting its toxicity [44].
To conclude, we report 4-aminophenols as a novel class of
RCCs capable of entering the redox cycle, thereby inducing the
formation of ROS and producing false positives in enzyme
inhibition assays. We propose that compounds with a 4-
aminophenol scaffold are eliminated from compound libraries to
be screened for inhibition of cysteine proteases. This could be of
great importance in HTS campaigns, where the exclusion of false
positive hits saves both time and resources otherwise spent on
follow up studies.
Supporting Information
Figure S1 Progress curves of cathepsin B activity
obtained in the presence of 4-aminophenol analogues
in redox-free conditions. 5 ml of DMSO (control) or
compounds 1 (A), 2 (B), 3 (C), 4 (D), 5 (E), 6 (F), 7 (G), 8 (H)
and H2O2 (I) (fifteen concentrations were used for each
experiment, for clarity only six are shown) and 5 ml of Z-Arg-
Arg-AMC (60 mM) were added to wells of a black microplate.
Reaction was initiated by adding 90 ml of cathepsin B (400 pM).
Formation of fluorescent degradation product was monitored
continuously at 380 nm excitation and 460 nm emission wave-
lengths using the minimal kinetic interval at 37uC. All kinetic
measurements were performed in duplicate. For time-dependent
inhibitors each progress curve was fitted to the equation P=v st +
(vi 2 vs)(1 2 e
2kobst)/kobs. The obtained kobs were plotted against
inhibitor concentration and the slope of linear fit yielded the
second-order rate constant kinact/KI.
(TIF)
Figure S2 Progress curves of cathepsin B activity
obtained in the presence of 4-aminophenol analogues
in the presence of 5 mM cysteine. 5 ml of DMSO (control) or
Figure 7. Schematic representation of 4-aminophenol induced ROS formation.
doi:10.1371/journal.pone.0027197.g007
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H2O2 (I) (fifteen concentrations were used for each experiment, for
clarity only six are shown) and 5 ml of Z-Arg-Arg-AMC (60 mM)
were added to the wells of a black microplate. The reaction was
initiated by adding 90 ml of cathepsin B (400 pM). Formation of
fluorescent degradation product was monitored continuously at
380 nm excitation and 460 nm emission wavelengths using the
minimal kinetic interval at 37uC. All kinetic measurements were
performed in duplicate. For time-dependent inhibitors each
progress curve was fitted to the equation P=v st + (vi 2 vs)(1 2
e
2kobst)/kobs. The obtained kobs were plotted against inhibitor
concentration and the slope of linear fit yielded the second-order
rate constant kinact/KI.
(TIF)
Figure S3 Binding of CA-074 is not affected by the redox
environment. Cathepsin B (1 mg) was incubated with cathepsin
B specific irreversible inhibitor CA-074 (200 mM) in a variety of
activation buffers containing no reducing agent, cystine, cysteine
or DTT (5 mM) and subsequently labeled with DCG-04 (2 mM).
Samples were then analyzed by SDS-PAGE and Western blotting.
The band intensities indicate cathepsin B activity.
(TIF)
Figure S4 Compounds 2–8 and H2O2 do not significantly
impair cathepsin B activity in the presence of 5 mM
cysteine, as shown with the DCG-04 probe. Cathepsin B
(1 mg) was incubated with compounds 2–8 and H2O2 (200 mM) in
the activation buffer containing 5 mM cysteine (A) and subse-
quently labeled with DCG-04 (2 mM). Samples were then analyzed
with SDS-PAGE and Western blotting. Band intensities correlate
with cathepsin B activity. Residual cathepsin B activity was
obtained by dividing individual band intensity by that of the
control (B). Data shown here are presented as means 6 SD, n=2.
(TIF)
Figure S5 pI calibration curve. The latter was obtained
using the Broad range pI calibration kit (pH 3.0–10.0) according
to the protocol of the manufacturer.
(TIF)
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